Sonoscape Medical Corp. Hits Day Low at CNY 24.90 Amid Price Pressure

Sonoscape Medical Corp., a large-cap player in the Pharmaceuticals & Biotechnology sector, has experienced a notable decline today, with its stock price dropping by 3.26%. The stock reached an intraday low of CNY 24.90, reflecting ongoing challenges in its financial performance. Over the past week, Sonoscape has seen a decrease of 3.97%, and its performance over the last month shows a decline of 6.39%. Year-to-date, the stock is down 5.75%, significantly underperforming the China Shanghai Composite, which has only dipped by 0.3%. In terms of long-term performance, Sonoscape has faced substantial hurdles, with a staggering 50.49% drop over the past three years. The company has reported negative results for the last four consecutive quarters, with net profit for the first nine months showing a decline of 68.17%. Additionally, the operating cash flow has reached a low of CNY -98.58 million, and the debt-equity ratio stands at -35.78%. With a price-to-earnings ratio of 828.00 and a return on equity of just 0.57%, Sonoscape Medical Corp. continues to grapple with significant financial pressures.